(American Journal of Gastroenterology) Real-world data confirmed the effectiveness of upadacitinib (Rinvoq) in Crohn's disease, with clinical remission achieved in 56% of patients at 6 months ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback